Health Care · Surgical & Medical Instruments & Apparatus

TLSI TriSalus Life Sciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 182666792 filings
Russell 2000

TLSI at a glance

TriSalus Life Sciences, Inc. (TLSI, SEC CIK 1826667) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), TriSalus Life Sciences, Inc. (TLSI) reported revenue of $45.2 million (up 53.4% from FY2024) and a net loss of $39.2 million. Diluted EPS was -$1.84.
  • As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding TriSalus Life Sciences, Inc. (TLSI) shares worth $30.6 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Szela Mary T on November 18, 2026 of 34,328 shares at $2.59 per share.
  • In the last 90 days, TLSI insiders reported 4 open-market purchases ($294K) and 4 open-market sales ($5K) on Form 4, a net purchase of $289K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$45.2M
+53.4% vs prior year
Insiders · 90 days
4 buys · 4 sells
Net +$289K
13F holders
18 funds
$30.6M · +1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Continued clinical-development risk, potential delays or unfavorable trial outcomes
  • Continued regulatory risk, failure to obtain or maintain required approvals
  • Continued liquidity risk, need for additional financing to support operations
  • Continued commercialization risk, limited market acceptance of TriSalus products

Management Discussion & Analysis

  • Q3 revenue $12.878M, up 11.3% YoY from $11.566M, driven by higher TriNav unit sales
  • Gross margin 86.2% vs 83.5% YoY, with gross profit $11.095M vs $9.660M
  • Sole TriNav product line, revenue growth driven by increased units and lower per-unit costs
  • Cash $41.1M vs $20.4M at December 31, 2025, with nine-month operating cash use $21.884M
  • $42.6M net public-offering proceeds, ongoing operating losses and need for additional capital highlighted as headwinds

AI summary of the TLSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Full operating and financial details contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $12.9M, up 11.3% YoY, signaling continued TriNav adoption despite slower-than-expected salesforce productivity
  • Gross margin expanded to 86.2% from 83.5%, while operating loss narrowed to $7.7M from $9.0M
Filed Sep 22, 2026Full analysis →

Item 8.01: Other Events

  • FDA 510(k) clearance received for TriNav Advance, removing a key U.S. regulatory barrier
  • Commercialization expected to commence, creating potential revenue opportunity for TriSalus
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results released for quarter ended June 30, 2026
  • Full operating metrics and management commentary contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $11.4M, up 1.7% year over year, signaling modest commercial growth despite expanded sales investment
  • Gross margin improved to 86.8% from 83.9%, supported by lower TriNav unit costs

AI summaries of TLSI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TLSI

Don't miss the next TLSI filing

  • Alerts as it files. A push when TLSI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TLSI, by share count.
  • Ask anything. An AI agent that reads every TLSI filing and answers with sources.

TLSI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Szela Mary TBuyNov 18, 2026$2.59
Gordon Gary B.BuyNov 17, 2026$2.20
Szela Mary TBuyNov 17, 2026$2.31
Marshak RichardSellNov 16, 2026$2.43
Wahlstrom MatsBuyNov 12, 2026$2.24
Stevens JenniferSellOct 5, 2026$4.39
Marshak RichardSellOct 5, 2026$4.39
Szela Mary TFOct 5, 2026$4.38

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$29.4M$45.2M
Gross Profit-$25.3M$38.2M
Operating Income--$36.2M-$26.9M
Net Income--$30.0M-$39.2M
Gross Margin-86.1%84.6%
Op. Margin--122.9%-59.7%
Net Margin--102.1%-86.9%
Balance Sheet
Total Assets$25.7M$24.0M$35.3M
Equity--$25.9M-$33.9M
ROE-116.0%115.8%
Per Share
EPS-$-1.31$-1.84
Cash Flow
Operating CF-$50.0M-$40.8M-$18.0M
CapEx-$345K$918K

Source: XBRL data in TriSalus Life Sciences, Inc. (TLSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TLSI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TLSI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202618$30.6M
Q2 202617$31.0M
Q1 202617$17.5M
Q4 202516$30.5M
Q3 202514$13.0M
Q2 202512$11.1M
Q1 202512$5.3M
Q4 20246$3.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 112 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TLSI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 17, 2026--
4Nov 16, 2026--
10-QNov 10, 2026Analysis
8-KNov 10, 2026Analysis-
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
8-KSep 22, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 6, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jun 29, 2026--
4May 15, 2026-
SC 13GMay 15, 2026-
4May 15, 2026-
4May 15, 2026-
4May 15, 2026-
4May 15, 2026-
4May 15, 2026-
8-KMay 14, 2026Analysis

Related Health Care companies

All Health Care →

TLSI SEC filings: frequently asked questions

Are TLSI insiders buying or selling?

In the last 90 days, TriSalus Life Sciences, Inc. (TLSI) officers, directors and 10% owners reported 4 open-market purchases worth $294,205 by 3 insiders and 4 open-market sales worth $5,435 by 3 insiders on Form 4, a net purchase of $288,770. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TLSI stock?

As of September 30, 2026, the largest TriSalus Life Sciences, Inc. (TLSI) holders among the 13F filers tracked by SignalX were BlackRock ($11.3 million), Vanguard Capital Management LLC ($7.4 million), State Street Corp ($2.9 million), Morgan Stanley ($1.8 million), Northern Trust ($1.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TLSI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), TriSalus Life Sciences, Inc. (TLSI) reported revenue of $45.2 million (up 53.4% from FY2024) and a net loss of $39.2 million. Diluted EPS was -$1.84. The figures come from the XBRL data in the 10-K.

What did TLSI report in its latest 8-K?

TriSalus Life Sciences, Inc. (TLSI) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026 announced.

What are the latest TLSI SEC filings?

TriSalus Life Sciences, Inc. (TLSI) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.

What is TLSI's SEC CIK number?

TriSalus Life Sciences, Inc. (TLSI)'s SEC Central Index Key (CIK) is 1826667. EDGAR lists every TLSI filing under that number.

Ask anything about TLSI

The research agent reads TLSI's filings, financials, insider trades and 13F holders, then answers with sources.